US Food and Drug AdministrationUS Food and Drug Administration
2019 has been a monumental year for new therapies for neurologic diseases. From migraine to MS, the FDA has approved numerous new treatments to address unmet needs in a range of disorders, including the first ever gene therapy for spinal muscular atrophy, as well as the first drug approved for episodic cluster headache. 

The approvals introduced several new classes of drugs, including the ditans and gepants in migraine, as well as novel formulations that can ease the administration of treatments and improve time to treatment effect in conditions like Parkinson disease and epilepsy. 

Look back on some of the most signficant FDA approvals in 2019 through the links below:

Lasmiditan - Acute Migraine

Istradefylline - Parkinson Disease

Pitolisant - Narcolepsy

Ubrogepant - Acute Migraine

Eculizumab - Neuromyelitis Optica Spectrum Disorder

Cenobamate - Partial-Onset Seizures

Riluzole Oral Film - Amyotrophic Lateral Sclerosis

Cladribine - Multiple Sclerosis

Midazolam Nasal Spray - Seizure Clusters

Zolgensma - Spinal Muscular Atrophy

Galcanezumab - Episodic Cluster Headache

Lemborexant - Insomnia

Golodirsen - Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

Solriamfetol - Excessive Daytime Sleepiness in Narcolepsy, Obstructive Sleep Apnea

Diroximel Fumarate - Relapsing MS, Clinically Isolated Syndrome